D
Sarepta Therapeutics, Inc. SRPT
$60.44 -$1.32-2.14% NASDAQ
Recommendation
Prev Close
$61.76
Volume
1,312,947
Avg Vol (90D)
1,568,013
Market Cap
$5.99B
Dividend & Yield
--
52-Week Range
$48.01 - $173.25
P/E (TTM)
25.86
EPS (TTM)
$2.39
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Can Solid Biosciences Challenge Sarepta in the DMD Market?
4/8/2025 - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
4/25/2025 - Globe Newswire
MetLife Investment Management LLC Purchases 4,422 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
4/25/2025 - MarketBeat
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. ...
4/24/2025 - GuruFocus
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
4/24/2025 - PR Newswire
Sarepta Therapeutics (SRPT): Among Billionaire George Soros' Small-Cap Stocks with Huge Upside Potential
4/24/2025 - Yahoo! Finance: News
Billionaire George Soros' 10 Small-Cap Stocks with Huge Upside Potential
4/23/2025 - Insider Monkey
Piper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
4/23/2025 - MarketBeat
Natixis Acquires 3,337 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
4/23/2025 - Ticker Report
Tower Research Capital LLC TRC Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
4/23/2025 - Ticker Report
MetLife Investment Management LLC Purchases 4,422 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
4/23/2025 - Ticker Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
4/22/2025 - PR Newswire
Sarepta Therapeutics Inc (SRPT) Announces First Quarter 2025 Financial Results Release SRPT ...
4/22/2025 - GuruFocus
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results SRPT Stock News
4/22/2025 - GuruFocus
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
4/22/2025 - GuruFocus
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
4/22/2025 - Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Short Interest Update
4/22/2025 - MarketBeat
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts?
4/22/2025 - Insider Monkey
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. ...
4/21/2025 - GuruFocus
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
4/21/2025 - Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Short Interest Up 25.8% in March
4/21/2025 - Ticker Report
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
4/21/2025 - Investor's Business Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
4/21/2025 - Globe Newswire
11 Most Promising Long-Term Stocks According to Analysts
4/21/2025 - Insider Monkey
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
2/19/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$1.90B
EBITDA (TTM)
$255.81M
EBIT (TTM)
$218.08M
Net Income (TTM)
$235.24M
Balance Sheet
Total Assets (Q)
$3.96B
Total Debt (Q)
$1.34B
Total Liabilities (Q)
$2.44B
Book Value Per Share (Q)
$15.77
Cash Flow
Cash from Operations (TTM)
-$205.79M
Cash from Investing (TTM)
$755.56M
Cash from Financing (TTM)
$124.81M
Net Change in Cash (TTM)
$674.58M
Filings
Filing Date
Friday, February 28, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
0.77
7-Day Total Return
11.06%
30-Day Total Return
-38.56%
60-Day Total Return
-47.65%
90-Day Total Return
-51.44%
Year to Date Total Return
-51.29%
1-Year Total Return
-52.56%
2-Year Total Return
-50.98%
3-Year Total Return
-21.20%
5-Year Total Return
-50.51%
52-week Low
Apr 09, 2025 - $48.01
52-week High
Jun 21, 2024 - $173.25
Valuation
Market Cap
$5.99B - Mid Cap
Enterprise Value
$5.98B
Price/Sales (TTM)
3.52
Price/Book (Q)
3.92
Dividends and Shares
Shares Outstanding
108.47M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sarepta.com
Phone Number
617 274 4000
Address
215 First Street
Cambridge, MA 02142
Country
United States
Year Founded
1980
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed